m+Medelevator.RU
← Поиск публикаций
Journal of drugs in dermatology : JDD · 2024

Efficacy of Topical Finasteride 0.25% With Minoxidil 5% Versus Topical Minoxidil 5% Alone in Treatment of Male Pattern Androgenic Alopecia.

СтатьяРандомизированное исследованиеСравнительное исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Asad Nazia, Naseer Maria, Ghafoor Rabia

Аннотация

BACKGROUND: Androgenetic Alopecia (AGA) (male pattern hair loss) is the most common form of alopecia in men, affecting 30% of men by the age of 30 years and 50% by the age of 50 years.

OBJECTIVE: To compare the efficacy of topical finasteride 0.25% with minoxidil 5% versus topical minoxidil 5% alone in the treatment of male pattern androgenic alopecia.

METHODS: A total of 164 male patients aged between 30 and 60 years, presenting with androgenic alopecia of more than 2 months duration, were included in this single-blind study conducted at the Department of Dermatology, JPMC, Karachi. The patients were randomly divided into two groups: Group A (topical finasteride 0.25% with minoxidil 5%) and Group B (topical minoxidil 5% alone). Patients were followed up for 12 weeks, and hair regrowth was assessed at each visit.

RESULTS: The mean age in Group A was 33.99±5.97 years, and in Group B, it was 33.91±5.71 years. At baseline, the mean salt score was 1.8±0.7 in both groups. The efficacy of the treatment was significantly higher in Group A (86.7%) compared to Group B (69.1%; P=0.006).

CONCLUSION: The combination of topical finasteride 0.25% with minoxidil 5% provides superior efficacy in the treatment of male pattern androgenic alopecia compared to topical minoxidil 5% alone. These findings support the use of this combination therapy as a potential treatment option for patients with androgenic alopecia. J Drugs Dermatol. 2024;23(11):1003-1008. doi:10.36849/JDD.7826.

Предметные рубрики MeSH

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты